Article
An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals at risk of coronary events. A WOSCOPS substudy.
European heart journal - 1 Jul 2002
White H L, Maqbool A, McMahon A D, Yates L, Ball S G, Hall A S, Balmforth A J
Abstract excerpt
AIMS: The Glycine389 variant of the beta-1 adrenergic receptor generates markedly less cAMP when stimulated in vitro than the more prevalent Arginine389 variant and may confer protection against coronary events similar to that observed with beta-blockers. The aim of this study was to ascertain whether this Glycine389 variant protects against coronary events. METHODS AND RESULTS: We identified the genotype at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
